Ποια είναι η τιμή για Solasia Pharma K.K. (4597)

Η τιμή για Solasia Pharma K.K. (4597) είναι $0.20877985

Ποια είναι η κεφαλαιοποίηση αγοράς για Solasia Pharma K.K. (4597)

Η κεφαλαιοποίηση αγοράς για Solasia Pharma K.K. (4597) είναι $57.00M

Solasia Pharma K.K. (4597) Τιμή και Κεφαλαιοποίηση Αγοράς

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.

Η τιμή για 4597	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$19,255.33 $57.00M	NVDA	$5.257T	+9,222,689.99%
$16,844.41 $57.00M	AAPL	$4.599T	+8,067,923.66%
$15,042.01 $57.00M	GOOG	$4.107T	+7,204,622.15%
$13,103.13 $57.00M	MSFT	$3.577T	+6,275,948.87%
$10,282.88 $57.00M	AMZN	$2.807T	+4,925,127.16%

Η τιμή για 4597

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$19,255.33 $57.00M